CPI-1612

bioavailable EP300/CBP HAT inhibitor

brain penetrant, orally efficacious in xeno.

from HTS and SBDD

ACS Med. Chem. Lett., Apr. 27, 2020

Constellation Pharma., Cambridge, MA

CPI-1612 is a pretty efficient-looking EP300/CBP histone acetyltransferase (HAT) inhibitor tool compound with demonstrated activity in a xenograft model and good higher species PK. While epigenetics targets like HATs have…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks